This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter and year end 2012 financial results on Wednesday, February 20, 2013, before the market opens. The Company's management will also hold a conference call on the same day at 9:00 A.M. Eastern time to provide an overview of its proprietary research and development programs, including CUDC-427, CUDC-907 and CUDC-101 as well as its partnered programs, including Erivedge® (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2012. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 9:00 A.M. Eastern time. The conference ID number is 98576283. The conference call can also be accessed on the Curis website at
www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. Eastern time, Tuesday, February 26, 2013. To access the replay, please call (855) 859-2056 from the United States or (404) 537-3406 from other locations and reference the conference ID number 98576283.
About Curis, Inc.
Curis is a drug development company seeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule IAP inhibitor, CUDC-907, a dual PI3K and HDAC inhibitor, and CUDC-101, an EGFR, Her2 and HDAC inhibitor. For more information, visit Curis' website at
The Curis, Inc. logo is available at
CONTACT: Michael P. Gray
CFO & COO